MS TRIAL RECEIVES POSITIVE SAFETY REVIEW FROM DSMB

BioMS Medical announced that its independent data safety monitoring board (DSMB) has reviewed data from its Phase II/III clinical trial of MBP8298 for the treatment of secondary progressive multiple sclerosis and recommended that the trial continue.

This is the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. The pivotal Phase II/III study is now ongoing at trial sites across Canada and the UK.